Known targets — ChEMBL curated mechanism
The experimentally established mechanism targets of Triaziquone. The predicted profile below is derived independently by chemical similarity — agreement is a validation signal, a miss is honest.
Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | PTGS1 | P23219 | 4/20 | 0.37 |
| ▸ | PTGS2 | P35354 | 4/20 | 0.37 |
| ▸ | DNMT1 | P26358 | 1/20 | 0.37 |
| ▸ | LMNA | P02545 | 3/20 | 0.35 |
| ▸ | F13A1 | P00488 | 3/20 | 0.35 |
| ▸ | SMN1; SMN2 | Q16637 | 3/20 | 0.35 |
| ▸ | MAPT | P10636 | 2/20 | 0.35 |
| ▸ | TP53 | P04637 | 1/20 | 0.35 |
| ▸ | STAT3 | P40763 | 1/20 | 0.35 |
| ▸ | HTT | P42858 | 1/20 | 0.35 |
| ▸ | TSHR | P16473 | 2/20 | 0.34 |
| ▸ | NFKB1 | P19838 | 1/20 | 0.34 |
| ▸ | PMP22 | Q01453 | 1/20 | 0.34 |
| ▸ | NPSR1 | Q6W5P4 | 2/20 | 0.34 |
| ▸ | GAA | P10253 | 2/20 | 0.34 |
| ▸ | MEN1 | O00255 | 1/20 | 0.34 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.34 |
| ▸ | NSD2 | O96028 | 1/20 | 0.33 |
| ▸ | TTR | P02766 | 1/20 | 0.33 |
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.33 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| Triaziquone SCHEMBL4299467 | 0.93 | DNMT1 (0.39) | DNMT1LMNASMN1; SMN2MAPTTP53 | |
| Triaziquone SCHEMBL8966183 | 0.93 | AKR1B1 (0.44) | PTGS1TSHRMEN1KMT2AKDM4E | |
| Palmitic Acid SCHEMBL2321669 | 0.92 | PPARG (0.46) | PTGS1LMNATSHRMEN1KMT2A | |
| Stearic Acid SCHEMBL6535255 | 0.92 | PPARG (0.46) | PTGS1LMNATSHRMEN1KMT2A | |
| Triaziquone SCHEMBL20544204 | 0.92 | PPARG (0.46) | PTGS1LMNATSHRMEN1KMT2A | |
| Triaziquone SCHEMBL10872529 | 0.90 | PPARG (0.45) | PTGS1LMNATSHRMEN1KMT2A | |
| Triaziquone SCHEMBL11744543 | 0.89 | PPARG (0.44) | PTGS1LMNATSHRMEN1KMT2A | |
| Stearic Acid SCHEMBL11745947 | 0.89 | PPARG (0.44) | PTGS1LMNATSHRMEN1KMT2A | |
| Triaziquone SCHEMBL11745026 | 0.89 | PPARG (0.44) | PTGS1LMNATSHRMEN1KMT2A | |
| Triaziquone SCHEMBL112850 | 0.88 | DNMT1 (0.35) | DNMT1SMN1; SMN2MAPTTP53STAT3 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 4 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-11884647-B2 | Compounds and methods for targeting pathogenic blood vessels | THE REGENTS OF THE UNIVERSITY OF CALIFORNIA (US) | 2024-01-30 | — | — | US | disclosed |
| US-20210147385-A1 | COMPOUNDS AND METHODS FOR TARGETING PATHOGENIC BLOOD VESSELS | THE REGENTS OF THE UNIVERSITY OF CALIFORNIA | 2021-05-20 | — | — | US | disclosed |
| WO-2021076886-A1 | 3-PHENYLSULPHONYL-QUINOLINE DERIVATIVES AS AGENTS FOR TREATING PATHOGENIC BLOOD VESSELS DISORDERS | THE REGENTS OF THE UNIVERSITY OF CALIFORNIA (US) | 2021-04-22 | — | — | WO | disclosed |
| US-5589104-A | Electrophoresis separation gel and a method for preparing an electrophoresis separation gel | BAMBECK GREGORY S (US) | 1996-12-31 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-11884647-B2 | Compounds and methods for targeting pathogenic blood vessels | TEK, KDR, LIPG | PTGS1 1204/4885PTGS2 1218/4885DNMT1 4564/4885 |
| US-20210147385-A1 | COMPOUNDS AND METHODS FOR TARGETING PATHOGENIC BLOOD VESSELS | TEK, KDR, LIPG | PTGS1 1204/4885PTGS2 1218/4885DNMT1 4564/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.